Higher levels of HDL cholesterol are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes

Diabetes Care

Volumn 29, Issue 1, 2006, Pages 78-82

  Molitch, Mark E ^a   Rupp, Demetra ^a   Carnethon, Mercedes ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALBUMINURIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE DURATION; DISEASE MARKER; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MALE; MICROALBUMINURIA; MULTIVARIATE ANALYSIS; PREVALENCE; PROLIFERATIVE RETINOPATHY; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; UNIVARIATE ANALYSIS; BLOOD; MIDDLE AGED; ONSET AGE; URINE;

ADULT; AGE OF ONSET; ALBUMINURIA; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 33644876955     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.29.01.06.dc05-1583     Document Type: Article

References (44)

1. U.S. Renal Data System: USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases, 2004
2. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification: Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39 (Suppl. 1):S1-S246, 2002
3. Gross JL, de Azevedo MJ Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28:164-176, 2005
4. Wang PH, Lau J, Chalmers TC: Metaanalysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 341:1306-1309, 1993
5. Molitch ME: The relationship between glucose control and the development of diabetic nephropathy in type I diabetes. Semin Nephrol 17:101-113, 1997
6. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.NEngl J Med 329:977-986, 1993
7. The DCCT Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial (DCCT). Kidney Int 47:1703-1720, 1995
8. Epidemiology of Diabetes Interventions and Complications (EDIC)/Diabetes Control and Complications Trial (DCCT) Study Group: Sustained effects of intensive treatment of type 1 diabetes mellitus on the development and progression of diabetic nephropathy. JAMA 290:2159-2167, 2003
9. Borch-Johnson K, Andersen PK, Deckert T: The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28:590-596, 1985
10. Jensen T, Borch-Johnson K, Kofoed-Enevoldsen A, Deckert T: Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 30:144-148, 1987
11. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 157:1413-1418, 1997
12. Valmadrid CT, Klein R, Moss SE, Klein BEK: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160:1093-1100, 2000
13. Fonseca VA: Risk factors for coronary heart disease in diabetes. Ann Intern Med 133:154-156, 2000
14. Eckel RH, McLean E, Albers JJ, Cheung MC, Bierman EL: Plasma lipids and microangiopathy in insulin-dependent diabetes mellitus. Diabetes Care 4:447-453, 1981
15. Vannini P, Ciavarella A, Flammini M, Bargossi AM, Forlani G, Borgnino LC, Orsoni G: Lipid abnormalities in insulin-dependent diabetic patients with albuminuria. Diabetes Care 7:151-154, 1984
16. Jensen T, Stender S, Deckert T: Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 31:142-145, 1988
17. Dullaart RPF, Dikkeschei LD, Doorenbos H: Alterations in serum lipids and apolipoproteins in male type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 32:685-689, 1989
18. Jones SL, Close DV, Mattock MB, Jarrett RJ, Keen H, Viberti GC: Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria. BMJ 298:487-490, 1989
19. Lahdenperä S, Groop P-H, Tilly-Kisi M, Kuusi T, Elliott TG, Viberti GC, Taskinen M-R: LDL subclasses in IDDM patients: relation to diabetic nephropathy. Diabetologia 37:681-688, 1994
20. Breyer JA, Bain RP, Evans JK, Nahman NS Jr, Lewis EJ, Cooper M McGill J, Berl T, the Collaborative Study Group: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 50:1651-1658, 1996
21. Klein R, Klein BEK, Moss SE, Cruickshanks KJ, Brazy PC: The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 22:743-751, 1999
22. Sibley SD, Hokanson JE, Steffes MW, Purnell JQ, Marcovina SM, Cleary PA, Brunzell JD: Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. Diabetes Care 22:1165-1170, 1999
23. Soedamah-Muthu SS, Colhoun HM, Taskinen M-R, Idzior-Walus B, Fuller JH, the EURODIAB IDDM Complications Study Group: Differences in HDL-cholesterol: apoA-I + apoA-II ratio and apoE phenotype with albuminuric status in type I diabetic patients. Diabetologia 43:1353-1359, 2000
24. Hadjadj S, Gallois Y, Simard G, Bouhanick B Passa P, Grimaldi A, Drouin P, Tichet J, Marre M, the GENEDIAB and DESIR Study Groups: Lack of relationship in long-term type 1 diabetic patients between diabetic nephropathy and polymorphisms in apolipoprotein å, lipoprotein lipase and cholesteryl ester transfer protein. Nephrol Dial Transplant 15:1971-1976, 2000
25. Campos-Pastor MM, Escobar-Jiménez F, Mezquita P, Herrera-Pombo JL, Hawkins-Carranza F, Luna JD, Azriel S, Serraclara A, Rigopoulos M: Factors associated with microalbuminuria in type 1 diabetes mellitus: a cross-sectional study. Diabetes Res Clin Pract 48:43-49, 2000
26. Chaturvedi N, Fuller JH, Taskinen M-R, the EURODIAB PCS Group: Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 24:2071-2077, 2001
27. Orchard TJ, Chang Y-F, Ferrell RE, Petro N, Ellis DE: Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complications Study. Kidney Int 62:963-970, 2002
28. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL, the DCCT/EDIC Research Group: Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int 64:817-828, 2003
29. Cusick M, Chew EY, Hoogwerf B, Agrón E, Wu LL, Lindley A, Ferris FL III, the Early Treatment Diabetic Retinopathy Study Research Group: Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int 66:1173-1179, 2004
30. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2496, 2001
31. Genest J Jr: Genetics and prevention: a new look at high-density lipoprotein cholesterol (Review). Cardiol Rev 10:61-71, 2002
32. National Center for Health Statistics: LDL cholesterol 1999-2000 data files [article online], 2000. Available from http://www.cdc.gov/nchs/about/ major/nhanes/currentnhanes.htm. Accessed 14 September 2004
33. Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk. Diabetes 49:1399-1408, 2000
34. Krolewski AS, Warram JH, Rand LI, Kahn CR: Epidemiologic approach to the etiology of type 1 diabetes mellitus and its complications. N Engl J Med 317:1390-1398, 1987
35. Kofoed-Enevoldsen A, Borch-Johnson K, Kreiner S, Nerup J, Deckert T: Declining incidence of persistent proteinuria in type 1 (insulin-dependent) diabetic patients in Denmark. Diabetes 36:205-209, 1987
36. Seaquist ER, Goetz GC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease: evidence for susceptibility to diabetic nephropathy. N Engl J Med 320:1161-1165, 1989
37. The DCCT Research Group: Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 46:1829-1839, 1997
38. Harjutsalo V, Katoh S, Sarti C, Tajima N, Tuomilehto J: Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes. Diabetes 53:2449-2454, 2004
39. Trevisan R, Viberti G: Genetic factors in the development of diabetic nephropathy. J Lab Clin Med 126:342-349, 1995
40. Parving H-H: Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 41:745-749, 1998
41. Krolewski AS: Genetics of diabetic nephropathy: evidence for major and minor gene defects. Kidney Intl 55:1582-1596, 1999
42. Chowdhury TA, Dyer PH, Kumar S, Barnett AH, Bain SC: Genetic determinants of diabetic nephropathy. Clin Sci 96:221-230, 1999
43. Bain SC, Gill GV, Dyer PH, Jones AF, Murphy M, Jones KE, Smyth C, Barnett AH: Characteristics of type 1 diabetes of over 50 years duration (the Golden Years Cohort). Diabet Med 20:808-811, 2003
44. Molitch ME, Rupp D, Carnethon M: Higher levels of HDL cholesterol (HDL cholesterol) are associated with a decreased likelihood of diabetic nephropathy (DN) in patients with long-standing type 1 diabetes (Abstract). Diabetes 54 (Suppl. 1):A198, 2005